Targeted Oncology24m
Clinical Perspectives: Question to Start Asking Is Who Not to Give Quadruplet CD38-Containing Regimens in Transplant-Eligible NDMM
Panelists discuss how the paradigm in transplant-eligible newly diagnosed multiple myeloma (NDMM) has shifted to considering which patients should not receive quadruplet CD38-containing regimens ...
Targeted Oncology20m
Exploring Maintenance Strategies Post Autologous Transplant
Panelists discuss how to optimize maintenance therapy following autologous stem cell transplantation by evaluating factors such as duration, drug selection, and risk-adapted approaches to maximize ...
Targeted Oncology21h
Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia
In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan ...
Targeted Oncology15h
Reevaluating Available Options for Anemia in Myelofibrosis
During a live event, Andrew Kuykendall, MD, discussed management of anemia before and during use of JAK inhibitor for ...
Targeted Oncology23h
FDA Grants Key Oncology Approvals and Designations in January 2025
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...